
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:1301</ns1:identifier>
    <ns1:title language="sr">Entezitis kao prediktor ispoljavanja psorijaznog artritisa</ns1:title>
    <ns2:alt_title language="sr">Entezitis as a predictor of the manifestation of psoriasis arthritis : doctoral dissertation</ns2:alt_title>
    <ns1:language>sr</ns1:language>
    <ns1:description language="sr"> Psorijaza je autoimunska sistemska inflamatorna bolest, čija je učestalost u
opštoj populaciji oko 2-3%. Pored promena na koži, bolesnik sa psorijazom je sa povišenim rizikom za pojavu depresije, gojaznosti, dijabetesa, inflamatornih bolesti creva, hipertenzije, bolesti srca. Najčešći komorbiiditet psorijaze je psorijazni artritis (PsA). Entezitis je jedan od tri ključna klinička znaka PsA.
Metode. Biće sprovedena prospektivna studija (studija slučaj-kontrola) kojom će biti obuhvaćeno 180 pacijenata obolelih od psorijaze (patohistološki
verifikovane), koji nisu lečeni sistemskom terapijom, izuzev uskospektralne UVB
fototerapije ili PUVA terapije.
Ovim bolesnicima će biti izveden ultrasonografski pregled enteza i kalkulacija
MASEI i GUESS skora, procena kvaliteta života kroz Dermatološki indeks
kvaliteta života (DLQI), popunjavanje i poređenje upitnika za procenu rizika
psorijaznog artritisa. Biće registrovani demografski i podaci o dosadašnjem toku
i trenutnoj aktivnosti bolesti (PASI skor), podaci o komorbiditetima.
Ultrasonografski pregledi enteza biće izvedeni u Institutu za radiologiju
Vojnomedicinske akademije u Beogradu, na ultrazvučnom aparatu
Resona 7 firme Mindray. Biće korišćena ultrazvučna sonda L14-6WU.
Očekivani rezultati. Prisustvo entezitisa na osnovu ultrasonografskog pregleda
enteza može imati prediktivnu vrednost za ispoljavanje psorijaznog artritisa i
utiče na kvalitet života kod bolesnika sa psorijazom, upitnici za procenu rizika
od psorijaznog artritisa mogu pružiti dodatne validne informacije, pojedini
klinički parametri (trajanje i aktivnost psorijaze) i stepen sistemske inflamacije
mogu imati prediktivnu vrednost za ispoljavanje psorijaznog artritisa i uticati na
kvalitet života kod bolesnika sa psorijazom. Prisustvo komorbiditeta (pogotovu na
lokomotornom sistemu), stepen depresije i subjektivna interpretacija bola mogu
imati negativnu prediktivnu vrednost za ispoljavanje psorijaznog artritisa.
Očekivani zaključak. Na osnovu dobijenih rezultata zaključićemo da
ultrasonografski pregled enteza predstavlja značajan korak u skrinigu pacijenata sa
psorijazom. Subjektivni parametri dobijeni preko upitnika za skrining bolesnika
sa psorijazom imaju određeni, ali manji značaj u odnosu na objektivni
ultrasonografski pregled.</ns1:description>
    <ns1:description language="en"> Psoriasis is an autoimmune systemic inflammatory disease, with a prevalence
of about 2-3% in the general population. In addition to skin changes, a patient with psoriasis is elevated risk of depression, obesity, diabetes, inflammatory bowel disease, hypertension, heart disease. The most common comorbidity of psoriasis is psoriatic arthritis (PsA). Entezitis represents one of the three key clinical signs of PsA.
Methods. A prospective study (case-control study) will be conducted to cover 180 patients with psoriasis (histopathologically verified) who have not been treated with systemic therapy, except for narrow-spectrum UVB phototherapy or PUVA therapy. These patients will undergo an ultrasonographic examination of the enthesis and calculations of MASEI and GUESS scores, assessment of quality of life through the Dermatological Quality of Life Index (DLQI), completing and comparing the psoriasis arthritis risk assessment questionnaire. Demographics and data on the existing and current activity of the
disease will be registered (PASI score), comorbidities data. The ultrasonographic examinations of the enthesis will be performed at the Institute of Radiology of the Military Medical
Academy in Belgrade, using the Mindray ultrasound device Resona 7. An L14-6WU ultrasonic probe will be used.
Expected results. The presence of enthesitis based on an ultrasonographic examination of
the enthesis may have predictive value for the manifestation of psoriatic arthritis and affect
the quality of life in patients with psoriasis, psoriatic arthritis risk assessment questionnaires
may provide additional valid information, individual clinical parameters (duration and activity of psoriasis) and degree of systemic inflammation may be predictive for manifestation of
psoriatic arthritis and affect quality of life in patients with psoriasis. Presence of comorbidities (especially on the locomotor system), degree of depression and subjective interpretation
of pain may have negative predictive value for the manifestation of psoriatic arthritis.
Expected conclusion. Based on the results obtained, we will conclude that an ultrasonographic examination of the enthesis represents a significant step in the screening of patients with psoriasis. Subjective parameters obtained through the screening questionnaire for
patients with psoriasis have certain, but less significance compared to objective ultrasonographic examination.</ns1:description>
    <ns1:description language="sr"></ns1:description>
    <ns2:identifiers>
      <ns2:identifier>ID=28360201 ; D-3385</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552101</ns2:resource>
      <ns2:identifier>7826</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>28360201</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2020-12-24T11:05:44.053Z</ns1:upload_date>
    <ns1:status>45</ns1:status>
    <ns2:peer_reviewed>no</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Dragan, 1959-, 2371175</ns3:firstname>
        <ns3:lastname>Dulović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Radiša, 1960-, 13583207</ns3:firstname>
        <ns3:lastname>Vojinović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>predsednik komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Milan, 1966-, 7731559</ns3:firstname>
        <ns3:lastname>Petronijević</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Ana, 1974-, 13583463</ns3:firstname>
        <ns3:lastname>Ravić-Nikolić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Mirjana, 1974-, 14762599</ns3:firstname>
        <ns3:lastname>Veselinović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>105 listova</ns1:format>
    <ns1:size>2679133</ns1:size>
    <ns1:location>http://phaidrabg.bg.ac.rs/o:1301</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>4</ns1:license>
  </ns1:rights>
  <ns1:annotation>
    <ns6:annotations>
      <ns6:date>2020-12-24T11:05:44.320Z</ns6:date>
    </ns6:annotations>
  </ns1:annotation>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:keyword language="sr" seq="1">psorijaza, psorijazni artritis, entezitis, kvalitet života</ns7:keyword>
    <ns7:keyword language="sr" seq="1">psoriasis, psoriatic arthritis, enthesitis, quality of life</ns7:keyword>
    <ns7:keyword language="sr" seq="1">616.517:616.72-002(043.3)</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1738</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>34A05</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:releaseyear>2020</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
